Fangzhou has signed a memorandum of understanding (MoU) with Novo Nordisk to collaborate on the management of serious chronic diseases including obesity and diabetes. Fangzhou will harness its AI ...

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities Published ...